Cover Image

BMP9 a possible alternative drug for the recently withdrawn BMP7?: new perspectives for (re-)implementation by personalized medicine

Promotion of rhBMP2 and rhBMP7 for the routine use to support fracture healing has been hampered by high costs, safety concerns and reasonable failure rates, imposing restrictions in its clinical use. Since there is little debate regarding its treatment potential, there is rising need for a better u...

Full description

Saved in:
Bibliographic Details
Main Authors: Sreekumar, Vrinda (Author) , Breitkopf-Heinlein, Katja (Author) , Dooley, Steven (Author)
Format: Article (Journal)
Language:English
Published: 2017
In: Archives of toxicology
Year: 2016, Volume: 91, Issue: 3, Pages: 1353-1366
ISSN:1432-0738
DOI:10.1007/s00204-016-1796-6
Online Access:Verlag, Volltext: http://dx.doi.org/10.1007/s00204-016-1796-6
Verlag, Volltext: https://link.springer.com/article/10.1007/s00204-016-1796-6
Get full text
Author Notes:Vrinda Sreekumar, Romina Haydeé Aspera-Werz, Gauri Tendulkar, Marie Karolina Reumann, Thomas Freude, Katja Breitkopf-Heinlein, Steven Dooley, Stefan Pscherer, Björn Gunnar Ochs, Ingo Flesch, Valeska Hofmann, Andreas Klaus Nussler, Sabrina Ehnert

MARC

LEADER 00000caa a2200000 c 4500
001 1578356113
003 DE-627
005 20230426230901.0
007 cr uuu---uuuuu
008 180808r20172016xx |||||o 00| ||eng c
024 7 |a 10.1007/s00204-016-1796-6  |2 doi 
035 |a (DE-627)1578356113 
035 |a (DE-576)508356113 
035 |a (DE-599)BSZ508356113 
035 |a (OCoLC)1341016417 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Sreekumar, Vrinda  |e VerfasserIn  |0 (DE-588)1110218133  |0 (DE-627)864824440  |0 (DE-576)475751043  |4 aut 
245 1 0 |a BMP9 a possible alternative drug for the recently withdrawn BMP7?  |b new perspectives for (re-)implementation by personalized medicine  |c Vrinda Sreekumar, Romina Haydeé Aspera-Werz, Gauri Tendulkar, Marie Karolina Reumann, Thomas Freude, Katja Breitkopf-Heinlein, Steven Dooley, Stefan Pscherer, Björn Gunnar Ochs, Ingo Flesch, Valeska Hofmann, Andreas Klaus Nussler, Sabrina Ehnert 
246 3 3 |a BMP 9 a possible alternative drug for the recently withdrawn BMP 7? 
264 1 |c 2017 
300 |a 14 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a First Online: 09 July 2016 
500 |a Im Titel sind die Zahlen "9" und "7" tiefgestellt 
500 |a Gesehen am 08.08.2018 
520 |a Promotion of rhBMP2 and rhBMP7 for the routine use to support fracture healing has been hampered by high costs, safety concerns and reasonable failure rates, imposing restrictions in its clinical use. Since there is little debate regarding its treatment potential, there is rising need for a better understanding of the mode of action of these BMPs to overcome its drawbacks and promote more efficacious treatment strategies for bone regeneration. Recently, BMP9, owing to its improved osteogenic potential, is gaining attention as a promising therapeutic alternative. Our study aimed at identifying specific gene expression patterns which may predict and explain individual responses to rhBMP7 and rhBMP9 treatments. Therefore, we investigated the effect of rhBMP7 and rhBMP9 on primary human osteoblasts from 110 donors and corresponding THP-1-derived osteoclasts. This was further compared with each other and our reported data on rhBMP2 response. Based on the individual donor response, we found three donor groups profiting from rhBMP treatment either directly via stimulation of osteoblast function or viability and/or indirectly via inhibition of osteoclasts. The response on rhBMP7 treatment correlated with expression levels of the genes BAMBI, SOST, Noggin, Smad4 and RANKL, while the response of rhBMP9 correlated to the expression levels of Alk6, Endoglin, Smurf1, Smurf2, SOST and RANKL in these donors. Noteworthy, rhBMP9 treatment showed significantly increased osteogenic activity (AP activity and Smad nuclear translocation) when compared to the two clinically used rhBMPs. Based on patient’s respective expression profiles, clinical application of rhBMP9 either solely or in combination with rhBMP2 and/or rhBMP7 can become a promising new approach to fit the patient’s needs to promote fracture healing. 
534 |c 2016 
700 1 |a Breitkopf-Heinlein, Katja  |d 1971-  |e VerfasserIn  |0 (DE-588)122473833  |0 (DE-627)705922375  |0 (DE-576)293287589  |4 aut 
700 1 |a Dooley, Steven  |d 1960-  |e VerfasserIn  |0 (DE-588)1028589190  |0 (DE-627)73128951X  |0 (DE-576)376074116  |4 aut 
773 0 8 |i Enthalten in  |t Archives of toxicology  |d Berlin : Springer, 1974  |g 91(2017), 3, Seite 1353-1366  |h Online-Ressource  |w (DE-627)25339015X  |w (DE-600)1458459-1  |w (DE-576)072283319  |x 1432-0738  |7 nnas  |a BMP9 a possible alternative drug for the recently withdrawn BMP7? new perspectives for (re-)implementation by personalized medicine 
773 1 8 |g volume:91  |g year:2017  |g number:3  |g pages:1353-1366  |g extent:14  |a BMP9 a possible alternative drug for the recently withdrawn BMP7? new perspectives for (re-)implementation by personalized medicine 
856 4 0 |u http://dx.doi.org/10.1007/s00204-016-1796-6  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://link.springer.com/article/10.1007/s00204-016-1796-6  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180808 
993 |a Article 
994 |a 2017 
998 |g 1028589190  |a Dooley, Steven  |m 1028589190:Dooley, Steven  |d 60000  |d 61100  |e 60000PD1028589190  |e 61100PD1028589190  |k 0/60000/  |k 1/60000/61100/  |p 7 
998 |g 122473833  |a Breitkopf-Heinlein, Katja  |m 122473833:Breitkopf-Heinlein, Katja  |d 60000  |d 61100  |e 60000PB122473833  |e 61100PB122473833  |k 0/60000/  |k 1/60000/61100/  |p 6 
999 |a KXP-PPN1578356113  |e 3020397715 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Vrinda Sreekumar, Romina Haydeé Aspera-Werz, Gauri Tendulkar, Marie Karolina Reumann, Thomas Freude, Katja Breitkopf-Heinlein, Steven Dooley, Stefan Pscherer, Björn Gunnar Ochs, Ingo Flesch, Valeska Hofmann, Andreas Klaus Nussler, Sabrina Ehnert"]},"recId":"1578356113","id":{"doi":["10.1007/s00204-016-1796-6"],"eki":["1578356113"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"2017"}],"physDesc":[{"extent":"14 S."}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"display":"Sreekumar, Vrinda","family":"Sreekumar","given":"Vrinda","role":"aut"},{"role":"aut","given":"Katja","family":"Breitkopf-Heinlein","display":"Breitkopf-Heinlein, Katja"},{"family":"Dooley","role":"aut","given":"Steven","display":"Dooley, Steven"}],"title":[{"title_sort":"BMP9 a possible alternative drug for the recently withdrawn BMP7?","subtitle":"new perspectives for (re-)implementation by personalized medicine","title":"BMP9 a possible alternative drug for the recently withdrawn BMP7?"}],"relHost":[{"title":[{"title":"Archives of toxicology","subtitle":"official journal of EUROTOX","title_sort":"Archives of toxicology"}],"note":["Gesehen am 11.08.25"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"pubHistory":["Volume 32, issue 1 (March 1974)-"],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1974-","dateIssuedKey":"1974","publisher":"Springer","publisherPlace":"Berlin ; Heidelberg"}],"id":{"eki":["25339015X"],"issn":["1432-0738"],"zdb":["1458459-1"]},"part":{"issue":"3","year":"2017","extent":"14","text":"91(2017), 3, Seite 1353-1366","pages":"1353-1366","volume":"91"},"recId":"25339015X","name":{"displayForm":["ed. on behalf of the Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie"]},"disp":"BMP9 a possible alternative drug for the recently withdrawn BMP7? new perspectives for (re-)implementation by personalized medicineArchives of toxicology"}],"titleAlt":[{"title":"BMP 9 a possible alternative drug for the recently withdrawn BMP 7?"}],"note":["First Online: 09 July 2016","Im Titel sind die Zahlen \"9\" und \"7\" tiefgestellt","Gesehen am 08.08.2018"]} 
SRT |a SREEKUMARVBMP9APOSSI2017 

Similar Items